<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580254</url>
  </required_header>
  <id_info>
    <org_study_id>GENERIC-LATANOPROST</org_study_id>
    <nct_id>NCT01580254</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma</brief_title>
  <acronym>LATANOPROST</acronym>
  <official_title>Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cantanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cantanzaro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines efficacy and tolerability of 3 different Latanoprost 0.005% eyedrops
      preparations, commercially available in Italy, in subjects affected by primary open angle
      glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, single blinded study of the duration of 3 months, involving subjects
      affected by POAG or OH under therapy with different Latanoprost drugs (Galaxia, Iopize or
      Latanoprost Rathiopharm).

      A total of 120 patients affected by POAG or OH newly diagnosed or already under topical
      therapy. will be recruited.

      After a recruitment visit to assest eligibility of each subject, a &quot;run-in&quot; therapy composed
      of timolol 0,5% 2 drops per day will be prescribed for 4 weeks.

      Then a baseline visit will be performed to evaluate IOP values and adverse effects in each
      subject. All subjects elegible for a therapy with a single dose of Latanoprost will be
      randomized into 3 arms.

      After 4 weeks of therapy a second visit will be made to assest IOP changes and safety.
      Therapy will be continued for another 4 weeks, and after that, a final visit will be made.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraocular pressure (IOP) in mmHg</measure>
    <time_frame>one month - two months</time_frame>
    <description>to evaluate intraocular pressure (IOP) reduction after one and two months treatment with latanoprost eyedrops</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear Break-Up Time (BUT) expressed in seconds</measure>
    <time_frame>one month - two months</time_frame>
    <description>After one and two months of therapy with latanoprost, tear BUT will be calculated, through the use of fluoresceine staining of the tear film.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intraocular Pressure (IOP)</condition>
  <condition>Tear Break-Up Time</condition>
  <arm_group>
    <arm_group_label>IOPIZE© eyedrops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is IOPIZE©</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GALAXIA© eyedrops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is GALAXIA©</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost RATIOPHARM© eyedrops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is Latanoprost RATIOPHARM©</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IOPIZE© Latanoprost eyedrops</intervention_name>
    <description>patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months</description>
    <arm_group_label>IOPIZE© eyedrops</arm_group_label>
    <other_name>IOPIZE© eyedrops (S.I.F.I. S.p.A. - Aci S. Antonio (CT), Italy)</other_name>
    <other_name>authorization numbers:</other_name>
    <other_name>039276011</other_name>
    <other_name>039276023</other_name>
    <other_name>039276035</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GALAXIA© Latanoprost eyedrops</intervention_name>
    <description>patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months</description>
    <arm_group_label>GALAXIA© eyedrops</arm_group_label>
    <other_name>GALAXIA© eyedrops (ALFA INTES Industria Terapeutica Splendore S.r.l. - Casoria (NA), Italy)</other_name>
    <other_name>authorization number:</other_name>
    <other_name>038622015</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost RATIOPHARM© latanoprost eyedrops</intervention_name>
    <description>patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months</description>
    <arm_group_label>Latanoprost RATIOPHARM© eyedrops</arm_group_label>
    <other_name>Latanoprost RATIOPHARM© eyedrops (RATIOPHARM GmbH - Ulm, Germany)</other_name>
    <other_name>authorization number:</other_name>
    <other_name>039468018/M</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ranged between 18 and 80

          -  Untreated IOP ranged between 21 and 30 mmHg

          -  IOP already treated with a single drug (monotherapy) ranged between 10 and 28 mmHg

        Exclusion Criteria:

          -  History of adverse events or any controindication to drugs administred during
             sperimentation, i. e. Latanoprost and Timolol.

          -  Narrow or closed iridocorneal angle.

          -  History of acute angle-closure glaucoma.

          -  Previous laser trabeculoplasty within 3 months before screening.

          -  Severe visual field defects within 10° from fixation in at least one eye (at least 2
             points with a p&lt;0,5 in a pattern deviation map obtained from a reliable 24-2 Sita
             Standard SAP).

          -  History of refractive surgery or any keratoplasty procedure, corneal opacities or
             diseases that make not suitable applanation tonometry.

          -  Use of contact lenses.

          -  BCVA less than 20/200.

          -  Ocular inflammation/infection occurring within three months before screening.

          -  History of bradicardia, systemic hypotension, bundle branch or any atrio-ventricular
             block

          -  Asthma

          -  Women of childbearing potential who were not using adequate contraceptive methods or
             who were pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Varano, M. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Catanzaro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Varano, M. D.</last_name>
    <phone>+3909613647365</phone>
    <email>luigi-varano@libero.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanni Scorcia, M. D.</last_name>
    <phone>+39 09613647135</phone>
    <email>scorcia@unicz.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Catanzaro - Eye Department</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Varano, M.D.</last_name>
      <phone>+3909613647365</phone>
      <email>luigi-varano@libero.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Scorcia, M. D.</last_name>
      <phone>+3909613647135</phone>
      <email>scorcia@unicz.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luigi Varano, M. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina De Luca</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>April 17, 2012</last_update_submitted>
  <last_update_submitted_qc>April 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cantanzaro</investigator_affiliation>
    <investigator_full_name>Luigi Varano, MD - Principal Investigator</investigator_full_name>
    <investigator_title>M. D.</investigator_title>
  </responsible_party>
  <keyword>Latanoprost</keyword>
  <keyword>IOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

